Avanos Medical, Inc. (AVNS) is a publicly traded Healthcare sector company. As of May 21, 2026, AVNS trades at $24.74 with a market cap of $1.16B and a P/E ratio of -2.90. AVNS moved -0.04% today. Year to date, AVNS is +118.74%; over the trailing twelve months it is +88.86%. Its 52-week range spans $9.30 to $24.91. Rallies surfaces AVNS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in AVNS news today?
Avanos Medical Agrees to $1.272B Buyout, Q1 Sales Rise 8.8%: Avanos agreed to be acquired by affiliates of American Industrial Partners in an all-cash deal valued at $1.272 billion and delivered first-quarter net sales of $182.2 million, up 8.8% year-over-year. Specialty Nutrition Systems net sales increased $22.9 million to $124 million with segment operating margin of 18.6%.
Holbrook Kerr sold 13.83K (~$152.17K) on Nov 18, 2025.
Holbrook Kerr sold 100 (~$1.10K) on Nov 18, 2025.
Holbrook Kerr sold 761 (~$8.38K) on Nov 18, 2025.
AVNS Analyst Consensus
AVNS analyst coverage data. Average price target: $0.00.
Common questions about AVNS
What changed in AVNS news today?
Avanos Medical Agrees to $1.272B Buyout, Q1 Sales Rise 8.8%: Avanos agreed to be acquired by affiliates of American Industrial Partners in an all-cash deal valued at $1.272 billion and delivered first-quarter net sales of $182.2 million, up 8.8% year-over-year. Specialty Nutrition Systems net sales increased $22.9 million to $124 million with segment operating margin of 18.6%.
Does Rallies summarize AVNS news?
Yes. Rallies summarizes AVNS news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is AVNS research on Rallies investment advice?
No. Rallies provides research, data, and educational context for AVNS. It does not provide personalized investment advice.
